Hi slick
the harsh, crappy truth is that at $600M mcap and still in the clinic the SP is probably fair value. Whilst in 2021 there were many pre revenue companies at multi B valuations, we are in a different world. Look at lke,nvx,peak msb... Not having a dig as I think immuno has a major role in future cancer care, but the mcap has major resistance imo until a clear path to revenue and drug submissions to FDA.
Cheers
Hi slickthe harsh, crappy truth is that at $600M mcap and still...
-
- There are more pages in this discussion • 1,916 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.7¢ |
Change
0.003(5.56%) |
Mkt cap ! $417.2M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.8¢ | 5.2¢ | $2.499M | 45.00M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1921794 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 1368288 | 7 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |